Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: A pilot trial (04-0274) and review of the literature

Transplant Infectious Disease

Volumn 14, Issue 3, 2012, Pages 259-267

  Chawla, J S ^a   Ghobadi, A ^a   Mosley, J ^a,b   Verkruyse, L ^a,b   Trinkaus, K ^a   Abboud, C N ^a   Cashen, A F ^a   Stockerl Goldstein, K E ^a   Uy, G L ^a   Westervelt, P ^a   Dipersio, J F ^a   Vij, R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Allogeneic hematopoietic stem cell transplant; CMV; Ganciclovir; Pre emptive therapy; Valganciclovir

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS LOAD;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84862183014     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00689.x     Document Type: Article

References (35)

1. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
2. Qamruddin AO, Oppenheim BA, Guiver M, Mutton KJ, Chopra R. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301-306.
3. Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol 2001; 39: 4362-4369.
4. Trenschel R, Ross S, Hüsing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2001; 25: 665-672.
5. Manteiga R, Martino R, Sureda A, et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 1998; 22: 899-904.
6. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
7. Winston DJ, Young JH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111: 5403-5410.
8. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003; 36: 749-758.
9. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind-study. Blood 1996; 88: 4063-4071.
10. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
11. Salzberger B, Bowden RA, Hackman R, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502-2508.
12. Scheinberg P, Melenhorst JJ, Brenchley JM, et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T-cells in the donor. Blood 2009; 114: 5071-5080.
13. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 777-781.
14. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV seropositive recipients of allogeneic bone marrow transplants. Clinical Infect Dis 1997; 24: 901-907.
15. Vij R, Khoury H, Brown R, et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant 2003; 32: 703-707.
16. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10, 000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006; 37: 51-56.
17. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
18. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113.
19. Lim ZY, Cook G, Johnson PR, et al. Results of a Phase I/II British Society of Bone Marrow Transplantation Study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res 2009; 33: 244-249.
20. De la Cruz-Vicente F, Cerezuela Martinez P, Gil-Espárraga E, et al. Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients. Transplant Proc 2008; 40: 3102-3103.
21. Busca A, de Fabritiis P, Ghisetti V, et al. Oral valganciclovir as preemptive therapy for cytomegalovirus post allogeneic stem cell transplantation. Transpl Infect Dis 2006; 9: 102-107.
22. Takenaka K, Eto T, Nagafuji K, Kamezaki K, et al. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2009; 89: 231-237.
23. Pastano R, Gigli F, Andreola G, Clabrese L, Peccatori F, Martinelli G. Valganciclovir is safe and effective as pre-emptive treatment for CMV infection in allogeneic hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2006; 108: (Abstract 5300).
24. De La Camara R, Vazquez L, Lopez J, Solano C, Serrano D, Gracia-Noblejas A. Prospective study of oral valganciclovir for pre-emptive therapy of cytomegalovirus after allogeneic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2009; 114: (Abstract 1168).
25. Sanchez JE, Storch GA. Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA. J Clin Microbiol 2002; 40: 2381-2386.
26. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851-856.
27. Van der Heiden PLJ, Kalpoe JS, Barge RM, Willemze R, Kroes ACM, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693-698.
28. Focosi D, Benedetti E, Maggi F, et al. Preemptive valganciclovir for cytomegalovirus infection in hematological patients. Transpl Infect Dis 2008; 10: 375-376.
29. Schulenburg A, Watkins-Riedel T, Greinix HT, et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001; 28: 765-768.
30. Deback C, Fillet AM, Dhedin N, et al. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 2007; 40: 173-179.
31. Bressollette-Bodin C, Coste-Burel M, Besse B, André-Garnier E, Ferre V, Imbert-Marcille BM. Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy. J Med Virol 2009; 81: 90-98.
32. Hassan-Walker AF, Kidd IM, Sabin C, Sweny P, Griffiths PD, Emery VC. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipient. J Med Virol 1999; 58: 182-187.
33. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
34. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
35. Lilleri D, Baldanti F, Gatti M, et al. Use of a DNAaemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem cell transplant compared with qualitative pp65 antigenemia. Blood 2007; 110: 2757-2760.